Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE) stock performance was 27.14% in last session and finished the day at $11.15. Traded volume was 295,227.00 shares in the last session and the average volume of the stock remained 34,881.00 shares. Fate Therapeutics Inc. (NASDAQ:FATE) insider ownership is 1.20%.

Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced on 10 march that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). Synthetic Biologics Inc. (NYSEMKT:SYN) rose 6.10% to $3.13 yesterday on volume of 3.62 million shares. The intra-day range of the stock was $2.98 – $3.20. Synthetic Biologics Inc. (NYSEMKT:SYN) has a market capitalization of 139.77 million.

Celladon Corp (NASDAQ:CLDN) on Mar. 4 announced it has completed enrollment and randomized 250 patients in the phase 2b trial titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease,” known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure. Celladon Corp (NASDAQ:CLDN)’s stock on March 14, 2014 reported a higher of 8.05% to the closing price of $15.84. Its fifty two weeks range is $7.45 – $15.95. The total market capitalization recorded 271.01 million. The overall volume in the last trading session was 144,182.00 shares. In its share capital, Celladon Corp (NASDAQ:CLDN) has 17.11 million outstanding shares.

Kindred Biosciences (NYSE:KIN) was downgraded by stock analysts at Roth Capital from a “buy” rating to a “neutral” rating in a report issued on Friday, TheFlyOnTheWall.com reports. They currently have a $25.00 price target on the stock, up from their previous price target of $20.00. Roth Capital’s price objective points to a potential upside of 2.46% from the company’s current price. On Friday, shares of Kindred Biosciences Inc. (NASDAQ:KIN) dropped -1.94% to close the day at $24.24. Company return on investment (ROI) is – and its monthly performance is recorded as 25.47%.